Dianthus Therapeutics Launches $400M Public Offering Plan
New York, United States & Waltham, Massachusetts – March 9, 2026 Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
New York, United States & Waltham, Massachusetts – March 9, 2026 Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused...
NEW HAVEN, Conn., Feb. 5, 2026 — Veradermics, Incorporated, a late clinical-stage biopharmaceutical company focused on dermatology therapeutics, announced...
